We are live on ! Find out more
PBE icon

Invesco Biotechnology & Genome ETF
PBE

60 hedge funds and large institutions have $92.6M invested in Invesco Biotechnology & Genome ETF in 2013 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 10 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 6

110% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 10

53% more capital invested

Capital invested by funds: $60.7M → $92.6M (+$31.9M)

18% more funds holding

Funds holding: 51 → 60 (+9)

4.78% more ownership

Funds ownership: 27.71% → 32.49% (+4.8%)

Holders
60
Holders Change
+9
Holders Change %
+17.65%
% of All Funds
1.74%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
21
Reduced
10
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$9.3M
2
Bank of America
Bank of America
North Carolina
+$7.15M
3
U
UBS
Switzerland
+$5.32M
4
Wells Fargo
Wells Fargo
California
+$4.77M
5
AIG
American International Group
New York
+$691K

Top Sellers

Rank Fund Capital Flow
1
PFG
Pacific Financial Group
Washington
-$1.77M
2
VKH
Virtu KCG Holdings
New York
-$676K
3
CWM
Concert Wealth Management
California
-$661K
4
WBG
Wharton Business Group
Pennsylvania
-$293K
5
NCM
Niemann Capital Management
Nevada
-$239K
Name Holding Trade Value Shares
Change 		Change in
Stake
PSI
51
Pinnacle Summer Investments
Virginia
$13K -$5.38K -150 -30%
DADC
52
D.A. Davidson & Co
Montana
$10K – – –
Creative Planning
53
Creative Planning
Kansas
$7K – – –
MFS
54
MSI Financial Services
Massachusetts
$7K +$1.08K +30 +19%
BCMIO
55
Beacon Capital Management Inc (Ohio)
Ohio
$6K +$5.38K +150 New
AA
56
Apriem Advisors
California
$4K – – –
BFEC
57
Benjamin F. Edwards & Company
Missouri
$2K +$1.51K +42 New
NDSI
58
Newman Dignan & Sheerar Inc
Rhode Island
$1.28K -$45.7K -1,275 -4%
HR
59
Howe & Rusling
New York
$1K – – –
JG
60
Jefferies Group
New York
$1K +$1K +28 New
VKH
61
Virtu KCG Holdings
New York
– -$676K -19,286 Closed
CWM
62
Concert Wealth Management
California
– -$661K -18,644 Closed
FANJ
63
Financial Architects (New Jersey)
New Jersey
– -$26K -750 Closed
Nomura Holdings
64
Nomura Holdings
Japan
– -$24K -684 Closed
PAS
65
Partnervest Advisory Services
California
– -$7K -190 Closed
SMA
66
Simply Money Advisors
Ohio
– -$4K -120 Closed
1 2
3

PBE Hedge Fund Activity: Q4 2013 in Review

60 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q4 2013, worth a combined $92.6M — up 53% from $60.7M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new PBE positions and 6 closed out — a net gain of 9 holders — while 21 added to existing stakes and 10 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $9.3M. The largest seller was Pacific Financial Group, cutting an estimated $1.77M.

  • 60 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q4 2013, up from 51 in Q3 2013.
  • Funds reported $92.6M of Invesco Biotechnology & Genome ETF stock for Q4 2013, up 53% quarter-over-quarter.
  • 15 funds opened new Invesco Biotechnology & Genome ETF positions in Q4 2013 and 6 closed out, a net change of +9 holders.
  • The largest Invesco Biotechnology & Genome ETF buyer in Q4 2013 was Morgan Stanley, an estimated $9.3M added.
  • The largest Invesco Biotechnology & Genome ETF seller in Q4 2013 was Pacific Financial Group, an estimated $1.77M sold.

Based on aggregated 13F filings for Q4 2013.